Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer

References

1. Aldred M. J., Addy M., Bagg J., Finlay I. 1991; Oral health in the terminally ill: a cross-sectional pilot survey. Spec Care Dentist 11:59–62 [CrossRef]
   [Google Scholar]
2. Arias A., Arevalo M. P., Andreu A., Rodriguez C., Sierra A. 1996; Candida glabrata : in vitro susceptibility of 84 isolates to eight antifungal agents. Chemotherapy 42:107–111 [CrossRef]
   [Google Scholar]
3. Bagg J., Sweeney M. P., Lewis M. A. O., Jackson M. S., Coleman D., Al Mosaid A., Baxter W., McEndrick S., McHugh S. 2003; High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. Palliat Med 17:477–481 [CrossRef]
   [Google Scholar]
4. Berrouane Y. F., Hollis R. J., Pfaller M. A. 1996; Strain variation among and antifungal susceptibilities of isolates of Candida krusei . J Clin Microbiol 34:1856–1858
   [Google Scholar]
5. Clarke J. G. M., Wilson J., Von Haacke N. P., Milne L. J. R. 1987; Oral candidiasis in terminal illness. Health Bull (Edinb) 45:268–271
   [Google Scholar]
6. Cross L. J., Bagg J., Oliver D., Warnock D. 2000; Serum itraconazole concentrations and clinical responses in Candida -associated denture stomatitis patients treated with itraconazole solution and itraconazole capsules. J Antimicrob Chemother 45:95–99
   [Google Scholar]
7. Cuenca-Estrella M., Díaz-Guerra T. M., Mellado E., Monzón A., Rodríguez-Tudela J. L. 1999; Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis 18:432–435 [CrossRef]
   [Google Scholar]
8. Davies A. N., Brailsford S., Broadley K., Beighton D. 2002; Oral yeast carriage in patients with advanced cancer. Oral Microbiol Immunol 17:79–84 [CrossRef]
   [Google Scholar]
9. Debruyne D. 1997; Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 33:52–77 [CrossRef]
   [Google Scholar]
10. Donnelly S. M., Sullivan D. J., Shanley D. B., Coleman D. C. 1999; Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. Microbiology 145:1871–1882 [CrossRef]
    [Google Scholar]
11. Finlay I. G. 1986; Oral symptoms and candida in the terminally ill. Br Med J (Clin Res Ed 292:592–593 [CrossRef]
    [Google Scholar]
12. Hoffman H. L., Rathbun R. C. 2002; Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 11:409–429 [CrossRef]
    [Google Scholar]
13. Jobbins J., Bagg J., Addy M., Newcombe R. G., Finlay I. G. 1992a; Oral and dental disease in terminally ill cancer patients. BMJ 304:1612 [CrossRef]
    [Google Scholar]
14. Jobbins J., Bagg J., Parsons K., Finlay I., Addy M., Newcombe R. G. 1992b; Oral carriage of yeasts, coliforms and staphylococci in patients with advanced malignant disease. J Oral Pathol Med 21:305–308 [CrossRef]
    [Google Scholar]
15. Johnson L. B., Kauffman C. A. 2003; Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630–637 [CrossRef]
    [Google Scholar]
16. Johnson E. M., Warnock D. W., Luker J., Porter S. R., Scully C. 1995; Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 35:103–114 [CrossRef]
    [Google Scholar]
17. Laverdiere M., Hoban D., Restieri C., Habel F. 2002; In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50:119–123 [CrossRef]
    [Google Scholar]
18. Lopez J., Pernot C., Aho S., Caillot D., Vagner O., Dalle F., Durnet-Archeray M. J., Chavanet P., Bonnin A. 2001; Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies. J Hosp Infect 48:122–128 [CrossRef]
    [Google Scholar]
19. NCCLS 1997 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard . NCCLS document M27-A Wayne, PA: National Committee for Clinical Laboratory Standards;
    [Google Scholar]
20. Pelletier R., Loranger L., Marcotte H., de Carolis E. 2002; Voriconazole and fluconazole suceptibility of Candida isolates. J Med Microbiol 51:479–483
    [Google Scholar]
21. Perfect J. R., Marr K. A., Walsh T. J. & 8 other authors; 2003; Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122–1131 [CrossRef]
    [Google Scholar]
22. Purkins L., Wood N., Ghahramani P., Greenhalgh K., Allen M. J., Kleinermans D. 2002; Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546–2553 [CrossRef]
    [Google Scholar]
23. Ramage G., López-Ribot J. L. 2004 Fungal biofilms and drug resistance. In Pathogenic Fungi: Host Interactions and Emerging Strategies for Control , chapter 11 Edited by San Blas G., Calderone R. A. Norwich: Horizon Scientific Press;
    [Google Scholar]
24. Ramage G., Van de Walle K., Wickes B. L., López-Ribot J. L. 2001; A standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45:2475–2479 [CrossRef]
    [Google Scholar]
25. Rex J. H., Pfaller M. A., Walsh T. J. & 8 other authors; 2001; Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14:643–658 [CrossRef]
    [Google Scholar]
26. Reynes J., Bazin C., Ajana F., Datry A., Le Moing J. P., Chwetzoff E., Levron J. C. 1997; Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother 41:2554–2558
    [Google Scholar]
27. Ruhnke M., Schmidt-Westhausen A., Trautmann M. 1997; In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 41:575–577
    [Google Scholar]
28. Sobel J. D., Ohmit S. E., Schuman P., Klein R. S., Mayer K., Duerr A., Vazquez J. A., Rampalo A. 2001; The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 183:286–293 [CrossRef]
    [Google Scholar]
29. Sweeney M. P., Bagg J., Baxter W. P., Aitchison T. C. 1998; Oral disease in terminally ill patients with xerostomia. Oral Oncol 34:123–126 [CrossRef]
    [Google Scholar]